A cash-rich, asset-light fertility benefits leader with provable clinical ROI is expanding into mid-market and longitudinal women’s health—yet trades at “stagnation” multiples due to rebate, macro, and concentration fears.
Overview
Progyny is a leading managed fertility and family-building benefits platform serving primarily large, self-insured U.S. employers (and expanding internationally) through a B2B2C model: enterprise clients and health plans offer Progyny’s benefits to employees who become end-users of clinical services. The company disrupts traditional dollar-capped fertility benefits by using an outcomes-based episodic framework centered on the proprietary Smart Cycle—a bundled “treatment currency” that flexes with medical need and avoids harmful incentives like multi-embryo transfers. Revenue is driven by two integrated segments: Fertility Benefit Services (dominant contributor; $830.9M in 9M 2025, +14% YoY) monetized via utilization fees, network fees, and PEPM admin fees; and Pharmacy Benefit Services/Progyny Rx ($457.7M in 9M 2025, +4.6% YoY) monetized through drug dispensing and retained rebates. Progyny serves 530–550+ employers, including >70% of the Fortune 100, covering ~7.2M lives, and is now broadening TAM with Progyny Select for the fully insured mid-market plus menopause/postpartum offerings beginning 2026.